Alterations in beta-catenin expression and localization in prostate cancer.
about
Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic ImplicationsWnt/β-catenin signalling in prostate cancerPeroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stressBeta-catenin phosphorylated at threonine 120 antagonizes generation of active beta-catenin by spatial localization in trans-Golgi networkProstate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.Molecular genetics of prostate cancer: new prospects for old challengesEpithelial mesenchymal transition (EMT) in prostate growth and tumor progressionThe role of epithelial plasticity in prostate cancer dissemination and treatment resistanceβ-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma.p68/DdX5 supports β-catenin & RNAP II during androgen receptor mediated transcription in prostate cancer.Beta-catenin is elevated in human benign prostatic hyperplasia specimens compared to histologically normal prostate tissue.The role of adhesion molecules as biomarkers for the aggressive prostate cancer phenotype.Discrete functions of GSK3α and GSK3β isoforms in prostate tumor growth and micrometastasis.Mechanism of β-catenin-mediated transcriptional regulation of epidermal growth factor receptor expression in glycogen synthase kinase 3 β-inactivated prostate cancer cellsEffect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts.Expression and colocalization of β-catenin and lymphoid enhancing factor-1 in prostate cancer progressionAndrogen regulation of epithelial-mesenchymal transition in prostate tumorigenesisSuppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferationDevelopment of a method to isolate circulating tumor cells using mesenchymal-based capture.β-catenin as a prognostic factor for prostate cancer (PCa).In silico functional profiling of individual prostate cancer tumors: many genes, few functions.Oncogenic Wnt/β-catenin signalling pathways in the cancer-resistant epididymis have implications for cancer research.Pharmacological modulation of beta-catenin and its applications in cancer therapyDissecting Major Signaling Pathways throughout the Development of Prostate Cancer.Wnt signaling in castration-resistant prostate cancer: implications for therapy.TRPM4 regulates Akt/GSK3-β activity and enhances β-catenin signaling and cell proliferation in prostate cancer cells.Glycogen synthase kinase-3 inhibitors suppress the AR-V7-mediated transcription and selectively inhibit cell growth in AR-V7-positive prostate cancer cells.SOX9 drives WNT pathway activation in prostate cancer.Hsp27 regulates EGF/β-catenin mediated epithelial to mesenchymal transition in prostate cancer.Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.Mutant epidermal growth factor receptor vIII increases cell motility and clonogenecity in a prostate cell line RWPE1.Targeted proteomic approach in prostatic tissue: a panel of potential biomarkers for cancer detection.Primary cilia are lost in preinvasive and invasive prostate cancer.miR-223 promotes colon cancer by directly targeting p120 catenin.MYC and Prostate CancerCalcium and Nuclear Signaling in Prostate Cancer.Frequently rearranged and overexpressed δ-catenin is responsible for low sensitivity of prostate cancer cells to androgen receptor and β-catenin antagonists.
P2860
Q28076060-ADF4D46B-8176-4A54-A69D-ED344A6B99EDQ28269116-53FEA1F3-35DB-42BA-949A-0B44617BB5BBQ28295105-0701A869-2B57-4EA7-9A27-406FE556193AQ28482268-935C00C0-13AC-44C8-97B4-2B324B4F1D49Q30409623-A93A3684-FE73-4DA1-BF1E-BE66AE7D1F87Q34127462-5CDFC53C-C0C5-426E-8870-6CF79AFF886FQ34397291-A76E9A7B-5EC4-4E10-AF7F-76678D1935C6Q34505037-138F1D6D-70C9-4393-8950-33F1BA28A3A1Q34539930-A79C8E3F-1214-4639-A8D5-EB388F002372Q34562695-67251DC4-A0BA-4AD2-94A0-CC3E1635DA11Q34978719-B25F44AA-78F8-4AC0-B39D-815496283215Q35072541-BD525B9E-10DA-46FD-9788-4109AE76DE72Q35742439-DCDD1DDC-2028-4D32-8A1B-85F47B7980CBQ36002945-41970D77-A83C-4018-B86B-A7EE47516BBEQ36048716-5996DD0A-C3D6-4577-B75F-47BB819D33BDQ36796016-FF6AD0B4-8028-4F0D-9B52-874D003F4F91Q36827512-2C62B200-8080-4742-BA48-687DE970B7D0Q37086749-5F42D8DC-7D51-4127-9686-29D3A90E0D12Q37325146-9242AFF1-F326-4160-BCD6-A0D599C8A8A5Q37579140-254C0493-6955-40D0-B9C6-72417BF8BE58Q37580644-369EEAA7-9378-458A-8F0F-C879A2AFC263Q38060099-F9BED5A3-1008-48CF-AF8D-6600677CA14BQ38089341-D1A278E7-F437-4F2E-A637-AE265E7EE3D1Q38112122-042BD09B-9A7C-449A-A2F8-69AE2181B995Q38241850-19787A67-6C00-4D50-B560-1B5BF4B85943Q38671090-9994EFD7-90A2-4F9B-AE20-3CEEA473B53CQ38708121-B4A80817-D087-4A62-BFE2-ADEA3E0F6BE5Q38780862-E82AAB58-7D37-4E15-87A2-D47DCAAF86C2Q38965263-359E6D01-5438-4AF5-963A-FC76B5D1E1C8Q39093621-26B0C385-0476-45FB-B6FA-B4FA701022B4Q39835279-72387248-C740-42FA-A9C7-F16D42D44DFEQ41235302-0A64E3A4-38E4-48CD-9FBC-8440D7F1122EQ41298456-F30AC0C3-3474-4C08-99FD-34893B07B3CFQ42362761-460B754A-CB64-42FA-8BA4-4735359E82ACQ42731671-8876D323-0A5D-44F8-A72A-5473CEA8964EQ52578386-1BD2B54A-6289-4B2F-99FE-7D9F3509539FQ54936285-43222E77-E743-4C72-8D42-5DAC149C87E7
P2860
Alterations in beta-catenin expression and localization in prostate cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Alterations in beta-catenin expression and localization in prostate cancer.
@en
Alterations in beta-catenin expression and localization in prostate cancer.
@nl
type
label
Alterations in beta-catenin expression and localization in prostate cancer.
@en
Alterations in beta-catenin expression and localization in prostate cancer.
@nl
prefLabel
Alterations in beta-catenin expression and localization in prostate cancer.
@en
Alterations in beta-catenin expression and localization in prostate cancer.
@nl
P2093
P356
P1433
P1476
Alterations in beta-catenin expression and localization in prostate cancer.
@en
P2093
Anne Y Warren
Hayley C Whitaker
Hing Leung
Ian G Mills
Joanne Girling
P304
P356
10.1002/PROS.20780
P577
2008-08-01T00:00:00Z